BVF INC/IL Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001056807
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 44 positions · Total reported value $2.80B · Top-10 concentration 76.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 34.8% · 5 new · 9 cut · 2 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +26.0% · vs SPY +11.2% · Prev Value $3.14B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2025 13F filing, BVF INC/IL disclosed 44 equity positions with a combined reported value of $2.80B. The filing implies a focused portfolio: its ten largest positions account for 76.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2025 were MLTX ($932.26M), KYMR ($240.14M), RVMD ($183.30M). By sector, the heaviest allocations are Health Care 94.4%, Materials 0.0%. Versus the prior quarter, allocation shifted toward Health Care (+3.9pp) and away from Other (-3.9pp).
Versus the prior quarter, BVF INC/IL opened 5 new positions, trimmed 9 and fully exited 2, a turnover rate of 34.8% of positions. The portfolio's overlap with the prior quarter was 79% of names.
The largest new positions opened in Q2 2025 were IMCR ($32.14M), CBIO ($22.40M).
Of the 2 positions fully exited versus the prior quarter, the largest were LKFT ($36.54M), VERV ($31.55M), ITOS ($18.36M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
Fully Exited (vs previous quarter)
- LKFT LAKEFRONT BIOTHERAPEUTICS NV · prev qtr: $36.54M
- VERV VERVE THERAPEUTICS INC · prev qtr: $31.55M
- ITOS ITEOS THERAPEUTICS INC · prev qtr: $18.36M
- THRD THIRD HARMONIC BIO INC · prev qtr: $8.23M
- VIGL VIGIL NEUROSCIENCE INC · prev qtr: $7.14M
- ALLK ALLAKOS INC · prev qtr: $3.77M
- CTMX CYTOMX THERAPEUTICS INC. · prev qtr: $3.32M
- GLYC GLYCOMIMETICS INC · prev qtr: $2.00M
Insider Transactions (Form 4)
Latest BVF INC/IL buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-14 | U | XOMA Royalty Corp | 772,000 | — | SEC filing |
| 2026-07-14 | U | XOMA Royalty Corp | 412,000 | — | SEC filing |
| 2026-07-14 | U | XOMA Royalty Corp | 2,773,545 | — | SEC filing |
| 2026-07-14 | U | XOMA Royalty Corp | 3,635,758 | — | SEC filing |
| 2026-06-26 | Sell | Kymera Therapeutics, Inc. | 51,858 | $106.50 | SEC filing |
| 2026-06-26 | Sell | Kymera Therapeutics, Inc. | 113,289 | $106.50 | SEC filing |
| 2026-06-26 | Sell | Kymera Therapeutics, Inc. | 627,597 | $106.50 | SEC filing |
| 2026-06-26 | Sell | Kymera Therapeutics, Inc. | 837,914 | $106.50 | SEC filing |
Fund Profile
BVF INC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 44 positions worth $3.91B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 44 positions · $3.91B reported value (Q2 2026)
- Top 10 holdings = 65.6% of reported value
- Largest position: RVMD (REVOLUTION MEDICINES INC) at 14.2%
- Average position size: $88.89M
Sector Tilt
- Health Care 91.6%
- Financials 0.1%
- Materials 0.0%
- (classified holdings cover 92% of value)
Quarterly Activity
- Q2 2026: 5 new, 6 added, 9 reduced, 2 exited
- 24 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
19.75M | $932.26M | 33.30% | Hold | |
| 2 |
|
5.50M | $240.14M | 8.58% | Add | |
| 3 |
|
4.98M | $183.30M | 6.55% | Hold | |
| 4 |
|
3.21M | $177.47M | 6.34% | Add | |
| 5 |
|
1.69M | $176.44M | 6.30% | Hold | |
| 6 |
|
2.76M | $140.52M | 5.02% | Reduce | |
| 7 |
|
8.83M | $107.61M | 3.84% | Hold | |
| 8 |
|
1.91M | $75.60M | 2.70% | Hold | |
| 9 |
|
2.59M | $65.28M | 2.33% | Reduce | |
| 10 |
|
4.31M | $54.08M | 1.93% | Hold | |
| 11 |
|
4.40M | $46.47M | 1.66% | Hold | |
| 12 |
|
3.47M | $46.27M | 1.65% | Hold | |
| 13 |
|
7.75M | $44.74M | 1.60% | Hold | |
| 14 |
|
5.75M | $43.30M | 1.55% | Hold | |
| 15 |
|
19.82M | $40.24M | 1.44% | Hold | |
| 16 |
|
786.39K | $38.31M | 1.37% | Reduce | |
| 17 |
|
3.94M | $37.75M | 1.35% | Hold | |
| 18 |
|
1.77M | $36.74M | 1.31% | Hold | |
| 19 |
|
1.02M | $32.14M | 1.15% | New | |
| 20 |
|
5.66M | $25.53M | 0.91% | Hold | |
| 21 |
|
5.30M | $24.92M | 0.89% | Hold | |
| 22 |
|
5.30M | $22.56M | 0.81% | Hold | |
| 23 |
|
1.39M | $22.40M | 0.80% | New | |
| 24 |
|
2.74M | $21.54M | 0.77% | Hold | |
| 25 |
|
4.63M | $17.17M | 0.61% | Add | |
| 26 |
|
6.29M | $17.05M | 0.61% | Hold | |
| 27 |
|
7.00M | $16.80M | 0.60% | Hold | |
| 28 |
|
696.55K | $15.70M | 0.56% | Hold | |
| 29 |
|
8.75M | $14.87M | 0.53% | Hold | |
| 30 |
|
10.33M | $14.36M | 0.51% | Hold | |
| 31 |
|
3.40M | $14.13M | 0.51% | Add | |
| 32 |
|
1.15M | $9.24M | 0.33% | Reduce | |
| 33 |
|
588.34K | $7.61M | 0.27% | Reduce | |
| 34 |
|
5.23M | $7.58M | 0.27% | Add | |
| 35 |
|
4.01M | $5.37M | 0.19% | Hold | |
| 36 |
|
7.65M | $5.34M | 0.19% | Reduce | |
| 37 |
|
1.35M | $5.19M | 0.18% | Hold | |
| 38 |
|
1.03M | $5.13M | 0.18% | Reduce | |
| 39 |
|
686.04K | $2.14M | 0.08% | Hold | |
| 40 |
|
339.55K | $1.98M | 0.07% | Hold | |
| 41 |
|
917.83K | $1.61M | 0.06% | Hold | |
| 42 |
|
3.85M | $1.27M | 0.04% | Hold | |
| 43 |
|
945.40K | $586.15K | 0.02% | Hold | |
| 44 |
|
143.68K | $416.66K | 0.01% | Hold | |
FAQ
What did BVF INC/IL buy in 2025-Q2?
In its 2025-Q2 13F filing, BVF INC/IL reported 44 equity positions worth $2.80B in aggregate; its largest disclosed positions were MLTX ($932.26M), KYMR ($240.14M), RVMD ($183.30M).
How large is BVF INC/IL's portfolio?
BVF INC/IL reported $2.80B of long equity holdings across 44 positions as of 2025-Q2. Top-10 holdings account for 76.9% of reported value.
What is BVF INC/IL's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.